Recombinant Human Type-1 angiotensin II receptor-associated protein (AGTRAP)

What is the basic structure of AGTRAP?

AGTRAP (Angiotensin II Type 1 Receptor-Associated Protein) is a transmembrane protein with distinct structural domains. It contains three hydrophobic domains at the amino-terminal end, specifically at amino acid residues 14-36, 55-77, and 88-108. Additionally, AGTRAP possesses a hydrophilic cytoplasmic carboxyl-terminal tail spanning from residues 109-161. This structural arrangement is critical for its cellular localization and functional interactions with the AT1 receptor. The orientation of AGTRAP positions its amino terminus outside the cell, while its carboxyl terminus faces the cytoplasm, allowing for interaction with intracellular signaling molecules .

Where is AGTRAP primarily localized in cells?

AGTRAP displays a particulate distribution within cells and is localized in multiple cellular compartments. Electron microscopy reveals prominent presence in perinuclear vesicular membranes. Immunofluorescence colocalization analysis demonstrates that AGTRAP is distributed in intracellular vesicular compartments corresponding to endoplasmic reticulum, Golgi apparatus, and endocytic vesicles. Real-time tracking of AGTRAP-containing vesicles shows constitutive translocation toward the plasma membrane, indicating dynamic trafficking within the cell. This subcellular distribution pattern suggests AGTRAP plays roles in receptor trafficking and intracellular signaling pathways .

What is the primary function of AGTRAP in relation to the AT1 receptor?

AGTRAP functions as a modulator of angiotensin II-induced signal transduction through its interaction with the AT1 receptor. This interaction occurs between the carboxyl-terminal domain of AGTRAP (amino acids 110-120 appear critical) and the last 20 amino acid residues of the AT1 receptor. Functionally, AGTRAP modulates several AT1 receptor-mediated signaling outcomes, including a moderate decrease in inositol lipid generation, a marked reduction in angiotensin II-stimulated transcriptional activity of the c-fos promoter, and decreased cell proliferation. These effects indicate AGTRAP serves as a negative regulator of specific AT1 receptor signaling pathways .

What are the recommended methods for detecting AGTRAP expression in tissue samples?

For robust detection of AGTRAP expression in tissue samples, researchers should employ a multi-modal approach. Immunohistochemistry (IHC) provides excellent visualization of AGTRAP protein distribution within tissues and has been successfully used to compare expression between hepatocellular carcinoma tissues and paired adjacent tissues. For mRNA expression analysis, quantitative RT-PCR remains the gold standard, while RNA-seq offers a broader transcriptomic context. When designing primers or selecting antibodies for AGTRAP detection, target specificity is crucial due to potential cross-reactivity with related proteins. For protein quantification, western blotting with appropriate controls should be used, complemented by mass spectrometry for more detailed protein characterization. Always include appropriate positive and negative controls, and consider using tissue microarrays for high-throughput screening across multiple samples .

How can I effectively examine AGTRAP-AT1 receptor interactions in experimental settings?

To effectively examine AGTRAP-AT1 receptor interactions, multiple complementary approaches should be employed. Yeast two-hybrid assays have been successfully used to identify the interacting domains between AGTRAP and the AT1 receptor. For validation in mammalian systems, modified mammalian two-hybrid assays allow for full post-transcriptional processing of the transgenes. In vitro pulldown assays using recombinant proteins (such as GST-AGTRAP constructs and the C-terminal tail of AT1 fused to MBP) provide direct evidence of interaction without cellular cofactors. For cellular studies, co-immunoprecipitation followed by western blotting can confirm interactions in more physiological contexts. Fluorescence resonance energy transfer (FRET) or bimolecular fluorescence complementation (BiFC) techniques offer real-time visualization of protein interactions in living cells. Creating deletion mutants (particularly targeting amino acids 110-120 of AGTRAP) can help identify critical interaction domains .

What cell culture models are most appropriate for studying AGTRAP function?

The selection of appropriate cell culture models for studying AGTRAP function depends on the specific research questions. Hepatocellular carcinoma cell lines (such as HepG2, Hep3B, and Huh7) are valuable models when investigating AGTRAP's role in liver cancer, as AGTRAP has been shown to be overexpressed in HCC tissues. For studying basic AGTRAP-AT1 receptor interactions, HEK293 cells provide a clean background with minimal endogenous expression while maintaining efficient transfection capabilities. Vascular smooth muscle cells and renal tubular epithelial cells represent physiologically relevant models for investigating AGTRAP's role in cardiovascular and renal systems where angiotensin II signaling is prominent. Primary cells isolated from tissues of interest provide the most physiologically relevant context but may present technical challenges. When establishing stable cell lines overexpressing AGTRAP or AGTRAP mutants, researchers should be aware that constructs lacking the cytosolic tail and third transmembrane domain may exhibit toxicity, with cells showing rounding, detachment, and loss from the culture plate .

How does AGTRAP affect cell proliferation and what are the signaling pathways involved?

AGTRAP exerts significant effects on cell proliferation through multiple signaling pathways. Experimental evidence indicates that overexpression of AGTRAP decreases the rate of cellular proliferation, which is consistent with its inhibitory effect on angiotensin II-induced signaling. This anti-proliferative effect appears particularly pronounced with AGTRAP mutants lacking the cytosolic tail and third transmembrane domain, suggesting domain-specific functions. At the molecular level, AGTRAP inhibits both basal and angiotensin II-stimulated c-fos gene expression, which is crucial for cell cycle progression and proliferation. Pathway analysis suggests AGTRAP's involvement in the NF-κB and MAPK signaling cascades, both critical regulators of cellular proliferation and survival. The interaction between AGTRAP and the AT1 receptor may influence downstream effectors such as calcium mobilization and activation of kinase cascades that control cell growth. Additionally, AGTRAP likely has AT1 receptor-independent effects on cell proliferation, as evidenced by the toxicity observed with certain AGTRAP mutants even in the absence of angiotensin II stimulation .

How can AGTRAP be manipulated genetically to study its function in specific signaling pathways?

Genetic manipulation of AGTRAP offers powerful approaches to dissect its function in specific signaling pathways. CRISPR-Cas9 genome editing provides precise knockout or knockin capabilities, allowing creation of AGTRAP-null cell lines or introduction of tagged versions at endogenous loci. When designing guide RNAs, target exons encoding functional domains (particularly amino acids 110-120) for maximum disruption effect. For reversible and dose-dependent studies, inducible expression systems (Tet-On/Off) allow temporal control of AGTRAP expression. Domain-specific mutants are particularly informative; constructs lacking the C-terminal domain (amino acids 110-161) fail to bind AT1 receptors and form prominent perinuclear vesicle clusters, while those with mutations in the transmembrane domains affect cellular localization. For pathway-specific analysis, reporter assays (such as c-fos promoter-luciferase constructs) can quantify AGTRAP's effect on transcriptional regulation. Co-expression with constitutively active or dominant-negative forms of pathway components (like NF-κB or MAPK cascade members) can establish epistatic relationships. When interpreting results, consider that AGTRAP may have AT1 receptor-independent functions that influence experimental outcomes .

What are the challenges in developing recombinant AGTRAP for research applications?

Developing recombinant AGTRAP presents several technical challenges that researchers must address. As a transmembrane protein with three hydrophobic domains, AGTRAP is difficult to express in soluble form in conventional bacterial systems. Expression in eukaryotic systems (insect cells, mammalian cells) is preferable but yields lower protein quantities. When designing expression constructs, inclusion of suitable purification tags (His, GST) is essential, but placement requires careful consideration to avoid disrupting functional domains, particularly the critical C-terminal interaction region (amino acids 110-120). For functional studies, recombinant AGTRAP should retain proper folding and post-translational modifications. Truncated constructs containing only the cytoplasmic C-terminal domain (amino acids 109-161) may be easier to produce for interaction studies but lack the context of membrane domains. Verification of biological activity requires demonstration of AT1 receptor binding capability, preferably through in vitro binding assays with the receptor's C-terminal tail. For structural biology applications, detergent optimization is critical for maintaining native conformation during extraction from membranes. Finally, storage conditions significantly impact stability; glycerol addition and avoidance of freeze-thaw cycles are recommended for maintaining functional integrity .

How can bioinformatic approaches be utilized to investigate AGTRAP's role in different cellular contexts?

Bioinformatic approaches provide powerful tools for investigating AGTRAP's role across multiple cellular contexts. Single-cell RNA sequencing data analysis reveals cell type-specific expression patterns and potential co-expression networks unique to particular cell populations. For cancer research, mining The Cancer Genome Atlas (TCGA) through platforms like UALCAN and LinkedOmics allows correlation of AGTRAP expression with clinical parameters, mutation status, and survival outcomes across multiple cancer types beyond HCC. Differential expression analysis between normal and disease states helps identify context-specific regulation patterns. Protein-protein interaction network analysis using databases like STRING can predict functional partners beyond the AT1 receptor, generating testable hypotheses about novel interaction partners. Gene Ontology and KEGG pathway enrichment analyses of genes co-expressed with AGTRAP identify biological processes and signaling pathways potentially influenced by AGTRAP. For immune contextualization, TIMER database analysis quantifies correlations between AGTRAP expression and immune cell infiltration markers. When conducting these analyses, researchers should apply appropriate statistical corrections for multiple testing (such as Benjamini-Hochberg) and validate key findings experimentally .

What is the relationship between AGTRAP expression and immune cell infiltration in cancer?

AGTRAP expression demonstrates significant positive correlations with immune cell infiltration in cancer microenvironments, particularly in hepatocellular carcinoma. Comprehensive analysis using the TIMER database reveals that AGTRAP expression positively correlates with infiltration of multiple immune cell types, including CD8+ T cells, CD4+ T cells, B cells, macrophages, dendritic cells, and neutrophils. This broad correlation pattern suggests AGTRAP may influence tumor immune microenvironment composition or serve as a marker of inflammatory processes within tumors. Furthermore, AGTRAP expression significantly correlates with T-cell exhaustion biomarkers, indicating potential involvement in immunosuppressive mechanisms within the tumor microenvironment. The mechanistic basis for these correlations likely involves AGTRAP's modulation of signaling pathways that regulate immune cell recruitment and function, possibly through NF-κB pathway involvement. These findings suggest AGTRAP may represent a link between angiotensin signaling and immune regulation in cancer, potentially influencing responsiveness to immunotherapeutic approaches .

How might modulating AGTRAP function affect response to cancer immunotherapies?

Modulating AGTRAP function could potentially influence response to cancer immunotherapies through several mechanisms. Given AGTRAP's positive correlation with T-cell exhaustion biomarkers, inhibiting AGTRAP function might reduce T-cell exhaustion within the tumor microenvironment, potentially enhancing the efficacy of immune checkpoint inhibitors targeting PD-1/PD-L1 or CTLA-4 pathways. AGTRAP's involvement in the NF-κB signaling pathway suggests it may influence inflammatory cytokine production that shapes the tumor immune microenvironment; modulating this function could potentially convert "cold" tumors to "hot" immunologically responsive tumors. Since AGTRAP correlates with multiple immune cell infiltrates, targeting its function might alter the balance of effector versus suppressive immune populations within tumors. Additionally, as a modulator of angiotensin II signaling, AGTRAP manipulation could intersect with emerging strategies combining angiotensin receptor blockers with immunotherapies. For clinical translation, research should focus on developing specific AGTRAP modulators that minimize off-target effects and identifying biomarkers (such as baseline AGTRAP expression levels) that predict which patients would benefit most from combined AGTRAP-targeted and immunotherapeutic approaches .

What statistical approaches are most appropriate for analyzing AGTRAP expression data in cancer studies?

When analyzing AGTRAP expression data in cancer studies, researchers should employ a comprehensive statistical approach tailored to the specific data types and research questions. For comparing AGTRAP expression between tumor and normal tissues, paired t-tests are appropriate for matched samples, while Mann-Whitney U tests are preferred for non-parametric distributions. Survival analysis should utilize Kaplan-Meier curves with log-rank tests for initial assessment, followed by Cox proportional hazards models to adjust for confounding variables like age, stage, and treatment. When evaluating AGTRAP as a diagnostic biomarker, receiver operating characteristic (ROC) curve analysis provides area under the curve (AUC) values - an AUC of 0.856 has been reported for AGTRAP in HCC. For correlating AGTRAP with clinical parameters, chi-square tests (categorical variables) or Spearman correlation (continuous variables) are recommended. When exploring gene co-expression networks, Pearson correlation followed by Benjamini-Hochberg false discovery rate correction controls for multiple testing. Gene set enrichment analyses require appropriate background gene sets and statistical methods like hypergeometric tests. For immune correlation analyses, purity-adjusted partial Spearman correlations should be used to account for tumor purity confounding. All analyses should be conducted using established statistical software like R (with packages such as "pROC", "survival", and "clusterProfiler") or SPSS, with clear reporting of statistical thresholds (typically p < 0.05) .

How can contradictory findings about AGTRAP function be reconciled in research?

Reconciling contradictory findings about AGTRAP function requires a systematic approach that considers multiple factors. First, cellular context differences may explain discrepancies - AGTRAP may function differently in various cell types due to differential expression of interaction partners or signaling components. Research should explicitly compare findings across cell types used. Methodological variations significantly impact results; differences in AGTRAP detection methods, overexpression levels, or knockout strategies should be carefully evaluated when comparing studies. Temporal dynamics merit consideration, as acute versus chronic modulation of AGTRAP may yield opposite effects due to compensatory mechanisms. Isoform-specific functions remain inadequately explored; potential alternative splicing or post-translational modifications may lead to functionally distinct AGTRAP variants. Domain-specific effects are crucial - the study showing toxicity with AGTRAP mutants lacking the cytosolic tail suggests domain-specific functions that may appear contradictory when studying different constructs. For mechanistic understanding, consider that AGTRAP has both AT1 receptor-dependent and independent functions, potentially leading to seemingly contradictory outcomes in different experimental setups. Meta-analysis approaches combining data across multiple studies can help identify consistent patterns amid apparent contradictions. When designing new studies to resolve contradictions, include multiple cell types, timepoints, and methodological approaches within a single study to directly compare conditions .

What are the most promising directions for AGTRAP research beyond its role in angiotensin signaling?

Several promising research directions extend beyond AGTRAP's established role in angiotensin signaling. Investigation of AGTRAP's potential interaction with other G protein-coupled receptors would determine whether it functions as a broader regulator of GPCR trafficking and signaling rather than being specific to AT1 receptors. The surprising connection between AGTRAP and immune cell infiltration in cancer microenvironments warrants detailed mechanistic studies to elucidate how AGTRAP influences immune cell recruitment, activation, and exhaustion. AGTRAP's role in vesicular trafficking suggests potential involvement in broader cellular processes like autophagy, endocytosis, and secretory pathways that could be explored through proximity labeling approaches to identify the complete AGTRAP interactome. The observation that AGTRAP mutants lacking the cytosolic tail induce cell toxicity independent of AT1 receptor interaction points to unexplored cellular functions deserving investigation. Given AGTRAP's prognostic significance in HCC, screening other cancer types for similar correlations could identify additional contexts where AGTRAP influences disease progression. For translational impact, developing small molecules or peptides that specifically modulate AGTRAP-AT1 receptor interactions could provide novel therapeutic approaches for conditions ranging from hypertension to cancer .

How might single-cell analyses advance our understanding of AGTRAP function in heterogeneous tissues?

Single-cell analyses offer transformative potential for understanding AGTRAP function in heterogeneous tissues by providing unprecedented resolution of expression patterns and functional relationships. Single-cell RNA sequencing (scRNA-seq) can reveal cell type-specific expression profiles of AGTRAP across diverse cell populations within complex tissues like tumors or organs, identifying previously unrecognized cell types where AGTRAP may have important functions. Temporal single-cell analyses during disease progression or development can trace the dynamics of AGTRAP expression changes in specific cell lineages. Spatial transcriptomics techniques complement scRNA-seq by preserving tissue architecture information, allowing visualization of AGTRAP expression in relation to tissue microstructures and neighboring cell interactions. Single-cell ATAC-seq can identify cell type-specific regulatory elements controlling AGTRAP expression, while single-cell proteomics techniques may reveal post-translational modifications that regulate AGTRAP function in specific cellular contexts. For functional insights, CRISPR perturbation coupled with single-cell readouts (CROP-seq) can assess cell type-specific consequences of AGTRAP modulation within heterogeneous populations. In cancer research, these approaches could identify specific cellular subpopulations where AGTRAP expression drives prognostic outcomes. For clinical translation, single-cell profiles of AGTRAP expression in patient samples may reveal cellular signatures that predict treatment responses or disease progression with greater precision than bulk tissue analyses .

What structural biology approaches could advance understanding of AGTRAP-receptor interactions?

Advanced structural biology approaches could significantly enhance our understanding of AGTRAP-receptor interactions at the molecular level. Cryo-electron microscopy (cryo-EM) represents a particularly promising technique for resolving the structure of the full AGTRAP-AT1 receptor complex embedded in membranes, potentially capturing different conformational states during signaling events. For higher resolution analysis of specific interaction domains, X-ray crystallography of the AGTRAP C-terminal domain (amino acids 109-161) in complex with the AT1 receptor C-terminal tail could precisely map the critical interaction interface. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) offers advantages for studying the dynamics of AGTRAP-AT1 interactions under near-physiological conditions, revealing conformational changes upon binding. Nuclear magnetic resonance (NMR) spectroscopy is well-suited for analyzing the solution structure of the cytoplasmic domains and their interactions with signaling partners. Molecular dynamics simulations based on initial structural data can model how AGTRAP influences AT1 receptor conformational dynamics and interaction with G proteins or arrestins. For functional insights, site-directed mutagenesis guided by structural data can validate key interaction residues, particularly within the critical 110-120 amino acid region of AGTRAP. Cross-linking mass spectrometry approaches can capture transient interactions within the larger signaling complex. These structural insights would provide rational targets for developing modulators of AGTRAP-AT1 interactions with therapeutic potential .